Recruiting
Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nabpaclitaxel and carboplatin – NeoTRIP (Neoadjuvant therapy in triple negative breast cancer with antiPDL1).
Click here to download the summary of the study.pdf